title: Polyethylene glycol (PEG)-induced mouse model of choroidal neovascularization.
abstract: In this study, we describe a new method for inducing choroidal neovascularization (CNV) in C57BL/6 mice, an animal model of wet age-related macular degeneration (AMD). AMD is a disease that causes central blindness in humans. We injected PEG-8 subretinally in different doses (0.125-2 mg) to induce CNV. After PEG-8 injection, we examined CNV at several time points (days 3-42). We also used Western blotting, immunohistochemistry, and ELISA to examine the complement component C3 split products, C9, VEGF, TGF-β2, and basic FGF. As early as day 1 after treatment, we found that a single subretinal injection of 1 mg of PEG-8 increased the C3 split products and the C9, TGF-β2, and basic FGF levels in the retinal pigment epithelium-choroid tissue. By day 3 after PEG-8 injection, the intraocular activation of the complement system caused induction and progression of CNV, including new vessels penetrating the Bruch's membrane. At day 5 after PEG-8 injection, we observed a fully developed CNV and retinal degeneration. Thus, in this study, we present a new, inexpensive, and accelerated mouse model of CNV that may be useful to study AMD.
authors: Department of Ophthalmology, Jones Eye Institute, Pat and Willard Walker Eye Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
authors: Valeriy V
authors: VV
authors: Lyzogubov
authors: Ruslana G
authors: RG
authors: Tytarenko
authors: Juan
authors: J
authors: Liu
authors: Nalini S
authors: NS
authors: Bora
authors: Puran S
authors: PS
authors: Bora
mesh_terms: D000818:Animals; D020256:Choroidal Neovascularization / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D003176:Complement C3 / Q000378:metabolism; D003186:Complement C9 / Q000378:metabolism; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000009:adverse effects* / Q000494:pharmacology; D008268:Macular Degeneration; D051379:Mice; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000494:pharmacology; D013997:Time Factors; D053781:Transforming Growth Factor beta2 / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D003176:Complement C3; D003186:Complement C9; D004337:Drug Carriers; C509042:Tgfb2 protein, mouse; D053781:Transforming Growth Factor beta2; D042461:Vascular Endothelial Growth Factor A; C467480:vascular endothelial growth factor A, mouse; D011092:Polyethylene Glycols